GlobeNewswire Inc.··NaJunshi Biosciences Wins NMPA Nod for First Domestic Subcutaneous Anti-PD-1 Drug
Junshi Biosciences wins NMPA approval for JS001sc, first domestic subcutaneous anti-PD-1 drug across 12 indications, delivering clinical parity with IV formulation.
ENGNENGNWPhase 3 clinical trialcancer treatment